Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
December 08 2022 - 2:01AM
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of
care diagnostics company, today announced findings from its second
annual “Point of Care Diagnostics: A Clinician's View” U.S. survey,
designed to understand physicians’ perspectives on the latest point
of care diagnostics technologies available. This blinded survey
polled U.S. physicians on a number of aspects related to point of
care testing (POCT) to evaluate key concerns and benefits, testing
locations, environmental benefits, and changing outlooks and
attitudes on COVID-19 diagnostics.
Findings from the survey revealed a few central themes including
the ongoing time and bandwidth stresses felt by most clinicians,
the future growth of community testing, and, importantly, an
overwhelming focus on patient impact. In addition, the report
showed a significant increase in clinicians’ comfort with the
accuracy and dependability of POCT when compared to the 2021
report.
Key findings included:
- PATIENT CARE: Clinicians ranked ‘Improved
quality of care’ as the No.1 benefit of POCT, over reduced
operational costs and time saving benefits.
- STAFF TIME: The top concern for clinicians is
the speed of results with 9/10 of clinicians expressing they are
extremely to moderately concerned with wait times of laboratory
(not POC) results.
- LOCATION: More than two-thirds of clinicians
estimate the role of community health is expected to expand,
anticipating growth for self-testing in nursing homes, pharmacies,
and patients’ homes.
- ENVIRONMENT IMPACT: Three-fourths of
clinicians acknowledged the potential of POCT in reducing the
carbon footprint of testing by reducing patient visits, was
moderately to extremely important in their adoption of POCT.
- PATIENT COST: New this year is physicians’
concern for patient costs with ‘inexpensive for patient’ ranking in
the top half of desired attributes for COVID-19 testing options,
which was in the bottom half of attributes in 2021.
“The last few years have been incredibly challenging for
physicians across the country,” commented Pooja Pathak, LumiraDx
Chief Product Officer. “This survey allows us to get a pulse on how
these changes in healthcare are impacting physicians’ attitudes on
diagnostics, the stresses that they are feeling and how they are
looking for testing to support them in their patient management.
From these results we can see not only a growing comfort with point
of care testing, but also a growing need for the unique solutions
next-generation POCT provides through rapid and accurate
results.”
The nationwide blinded survey, conducted by a third-party, was
held online between October 7-14th surveying 200 U.S. general
practitioners in private, group practices as well as urgent
care.
The full survey results for both the U.S and U.K. reports are
available at go.lumiradx.com/clinicians-survey-2022.
About LumiraDxLumiraDx Limited (Nasdaq: LMDX)
is a next-generation point of care diagnostics company that is
transforming community-based healthcare. Its actively controlled
microfluidic technology provides fast, high performance and
accessible diagnostic solutions wherever the patient is for nearly
any testing scenario, creating unique testing options at the point
of need.
The company offers a broad menu of lab comparable tests on a
single portable Platform, with more than 30 assays on the market
and in the pipeline, covering infectious diseases, cardiovascular
diseases, diabetes, and coagulation disorders. The company also
supports high-complexity laboratory testing in an accessible
high-throughput format to leverage current molecular laboratory
operations.
Founded in 2014 and based in the UK, LumiraDx's diagnostic
testing solutions are being deployed globally by governments and
leading healthcare institutions across laboratories, urgent care,
physician offices, pharmacies, schools, and workplaces to help
screen, diagnose, and monitor wellness as well as disease.
More information on LumiraDx is available
at www.lumiradx.com.
Media Contact: Colleen.McMillen@lumiradx.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/366ee774-2af0-42e0-a55a-87741c93e2c9
LumiraDx (NASDAQ:LMDX)
Historical Stock Chart
From May 2024 to Jun 2024
LumiraDx (NASDAQ:LMDX)
Historical Stock Chart
From Jun 2023 to Jun 2024